We are live on ! Find out more
CNCE

Concert Pharmaceuticals, Inc.
CNCE

Delisted

CNCE was delisted on the 3rd of March, 2023.

Back to rankings

79 hedge funds and large institutions have $219M invested in Concert Pharmaceuticals, Inc. in 2017 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 27 increasing their positions, 21 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

169% more call options, than puts

Call options by funds: $592K | Put options by funds: $220K

29% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 21

12% more capital invested

Capital invested by funds: $195M → $219M (+$24.3M)

7% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 14

0% more funds holding

Funds holding: 79 → 79 (0)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
79
Holders Change
–
Holders Change %
0%
% of All Funds
1.97%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
15
Increased
27
Reduced
21
Closed
14
Calls
$592K
Puts
$220K
Net Calls
+$372K
Net Calls Change
+$882K

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$18.6M
2
SM
Senvest Management
New York
+$3.75M
3
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
+$2.87M
4
UBS Group
UBS Group
Switzerland
+$2.33M
5
ISL
Ingalls & Snyder LLC
New York
+$2.22M

Top Sellers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$6.68M
2
Citadel Advisors
Citadel Advisors
Florida
-$5.09M
3
DCM
Driehaus Capital Management
Illinois
-$3.28M
4
Invesco
Invesco
Georgia
-$1.48M
5
SAM
Senzar Asset Management
New York
-$1.11M
Name Holding Trade Value Shares
Change 		Change in
Stake
QI
26
QS Investors
New York
$1.35M -$22.1K -1,525 -2%
California Public Employees Retirement System
27
California Public Employees Retirement System
California
$1.25M – – –
Fisher Asset Management
28
Fisher Asset Management
Washington
$1.1M – – –
Morgan Stanley
29
Morgan Stanley
New York
$1.08M -$149K -10,259 -12%
First Manhattan
30
First Manhattan
New York
$1.02M +$1,000K +68,900 New
Prudential Financial
31
Prudential Financial
New Jersey
$958K -$489K -33,720 -34%
PP
32
PDT Partners
New York
$876K +$862K +59,393 New
Point72 Asset Management
33
Point72 Asset Management
Connecticut
$843K +$829K +57,134 New
Bank of America
34
Bank of America
North Carolina
$709K -$22.8K -1,571 -3%
DMK
35
David M. Knott
$664K +$653K +45,000 New
BCM
36
Bridgeway Capital Management
Texas
$621K – – –
State of New Jersey Common Pension Fund D
37
State of New Jersey Common Pension Fund D
New Jersey
$590K – – –
TA
38
Teachers Advisors
New York
$507K – – –
Goldman Sachs
39
Goldman Sachs
New York
$497K +$244K +16,795 +99%
Charles Schwab
40
Charles Schwab
California
$474K – – –
California State Teachers Retirement System (CalSTRS)
41
California State Teachers Retirement System (CalSTRS)
California
$420K -$47.9K -3,301 -10%
Swiss National Bank
42
Swiss National Bank
Switzerland
$410K – – –
AA
43
ALPS Advisors
Colorado
$330K +$28.7K +1,981 +10%
Squarepoint
44
Squarepoint
New York
$317K +$74K +5,100 +31%
Deutsche Bank
45
Deutsche Bank
Germany
$309K +$2.58K +178 +0.9%
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$302K +$2.83K +195 +1%
MCM
47
Manchester Capital Management
Vermont
$295K – – –
Invesco
48
Invesco
Georgia
$257K -$1.48M -101,787 -85%
New York State Common Retirement Fund
49
New York State Common Retirement Fund
New York
$239K – – –
Manulife (Manufacturers Life Insurance)
50
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$225K +$2.38K +164 +1%
1
2
3 4

CNCE Hedge Fund Activity: Q3 2017 in Review

79 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q3 2017, worth a combined $219M — up 12% from $195M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new CNCE positions and 14 closed out — a net gain of 1 holder — while 27 added to existing stakes and 21 trimmed.

The largest buyer was BVF Inc, adding an estimated $18.6M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $6.68M sold.

  • 79 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q3 2017, unchanged from Q2 2017.
  • Funds reported $219M of Concert Pharmaceuticals, Inc. stock for Q3 2017, up 12% quarter-over-quarter.
  • 15 funds opened new Concert Pharmaceuticals, Inc. positions in Q3 2017 and 14 closed out, a net change of +1 holder.
  • The largest Concert Pharmaceuticals, Inc. buyer in Q3 2017 was BVF Inc, an estimated $18.6M added.
  • The largest Concert Pharmaceuticals, Inc. seller in Q3 2017 was Adage Capital Partners, an estimated $6.68M sold.

Based on aggregated 13F filings for Q3 2017.